MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202621084912 A) filed by Dr. Nidhi Bais; Dr. Ravikant Gupta; Dr. Shubham Sharma; and Dr. Raghvendra Dubey on July 10, 2026, for Formulation And Evaluation Of Dry Powder Inhaler Of Aspirin, Clopidogrel, And Atorvastatin For Emergency Management Of Pulmonary Disease..
Inventors include Dr. Nidhi Bais; Dr. Ravikant Gupta; Dr. Shubham Sharma; and Dr. Raghvendra Dubey.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: Abstract The present invention relates to a pharmaceutical dry powder inhaler (DPI) formulation containing aspirin, clopidogrel, and atorvastatin for rapid emergency management of cardiovascular diseases including acute myocardial infarction, acute coronary syndrome, unstable angina, and related thrombotic events. The formulation comprises micronized particles having an aerodynamic particle size ranging from approximately 1–5 µm to enable efficient deposition within the pulmonary alveolar region. The inhaled formulation bypasses gastrointestinal absorption and first-pass hepatic metabolism, resulting in rapid systemic drug availability and faster therapeutic onset compared with conventional oral dosage forms. The invention further includes a multidose dry powder inhaler equipped with a metered-dose dispensing mechanism capable of accurately delivering the pharmaceutical composition. The formulation may be prepared using ultrasonic atomization followed by solvent evaporation and particle collection to obtain respirable micronized powder exhibiting excellent flowability and dispersibility. Pulmonary administration provides rapid platelet inhibition, lipid-lowering activity, improved endothelial protection, and reduced gastrointestinal adverse effects while enabling convenient, non- invasive administration during pre-hospital or emergency settings. The invention therefore provides an effective emergency drug delivery platform capable of improving early therapeutic intervention and potentially reducing morbidity and mortality associated with cardiovascular emergencies.
Disclaimer: Curated by HT Syndication.
